<DOC>
	<DOCNO>NCT00154336</DOCNO>
	<brief_summary>Imatinib member new class drug know signal transduction inhibitor . The purpose study evaluate efficacy , safety tolerability imatinib treatment rheumatoid arthritis combination methotrexate patient respond satisfactorily standard treatment , e.g . methotrexate .</brief_summary>
	<brief_title>A Study Imatinib 400 mg Once Daily Combination With Methotrexate Treatment Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>With diagnosis RA classify ACR 1987 revise criterion symptom least 6 month Functional status class I , II , III accord ACR 1991 revise classification criterion Patients treat MTX maximum tolerate dose least 3 month , stable dose route administration least 2 month prior study entry Disease activity criterion minimum 6 28 tender swollen joint baseline With current use DMARDs MTX . DMARDs include limited : biologic agent , thiolates ( Dpenicillamine , thiopronine ) , sulfasalazine , gold compound , antimalarial , cyclosporine A , azathioprine , leflunomide alkylating agent cyclophosphamide With DMRAD treatment use combination methotrexate within 1 month prior study entry . In case infliximab leflunomide , washout period 2 month require With therapy intraarticular injection , include intraarticular corticosteroid use within 1 month prior study entry Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Rheumatoid arthritis , imatinib , methotrexate</keyword>
</DOC>